open access

Ahead of print
Review paper
Early publication date: 2021-11-04
Get Citation

Maintenance avelumab in metastatic urothelial cancer patients

Jakub Kucharz1
DOI: 10.5603/OCP.2021.0021
Affiliations
  1. Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Ahead of print
REVIEW ARTICLES
Early publication date: 2021-11-04

Abstract

The treatment outcomes of patients with metastatic urothelial carcinoma remain poor. Despite the relatively high response rate to platinum-based chemotherapy, the median overall survival doesn't exceed 14 months. Immunotherapy with anti-PD-1/anti-PD-L1 antibodies in the second-line treatment shows significant activity but nearly 50% of patients are not eligible for such treatment because of poor performance status. Therefore, there is a need for new treatment strategies. In the phase III JAVELIN Bladder 100 clinical trial, the maintenance treatment with avelumab in patients who achieved disease control with platinum-based first-line chemotherapy resulted in prolongation of overall survival and progression-free survival with good safety profile.

Abstract

The treatment outcomes of patients with metastatic urothelial carcinoma remain poor. Despite the relatively high response rate to platinum-based chemotherapy, the median overall survival doesn't exceed 14 months. Immunotherapy with anti-PD-1/anti-PD-L1 antibodies in the second-line treatment shows significant activity but nearly 50% of patients are not eligible for such treatment because of poor performance status. Therefore, there is a need for new treatment strategies. In the phase III JAVELIN Bladder 100 clinical trial, the maintenance treatment with avelumab in patients who achieved disease control with platinum-based first-line chemotherapy resulted in prolongation of overall survival and progression-free survival with good safety profile.

Get Citation

Keywords

urothelial carcinoma; maintenance treatment; avelumab; immunotherapy

About this article
Title

Maintenance avelumab in metastatic urothelial cancer patients

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Review paper

Early publication date

2021-11-04

DOI

10.5603/OCP.2021.0021

Keywords

urothelial carcinoma
maintenance treatment
avelumab
immunotherapy

Authors

Jakub Kucharz

References (34)
  1. Bellmunt J, Orsola A, Leow JJ, et al. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii40–iii48.
  2. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068–3077.
  3. Santis MDe, Bellmunt J, Mead G, et al. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. J Clin Oncol. 2012; 30(2): 191–199.
  4. Balar A, Galsky M, Rosenberg J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017; 389(10064): 67–76.
  5. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11): 1483–1492.
  6. Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11): 1015–1026.
  7. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018; 391(10122): 748–757.
  8. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3): 312–322.
  9. Ma'koseh M, Salam M, Al-Wardat R, et al. Metastatic urothelial tumors progressing following first line chemotherapy: prognostic factors and importance of second line chemotherapy. J Clin Oncol. 2016; 34(15_suppl): e16036–e16036.
  10. Grivas P, Monk BJ, Petrylak D, et al. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Target Oncol. 2019; 14(5): 505–525.
  11. Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020; 6(3): e194489.
  12. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1274–1284.
  13. Mirza MR, Monk BJ, Herrstedt J, et al. ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22): 2154–2164.
  14. Friedlander M, Moore KN, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26): 2495–2505.
  15. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib mainte- nance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390: 1949–1961.
  16. García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017; 18(5).
  17. Powles T, Huddart RA, Elliott T, et al. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J Clin Oncol. 2017; 35(1): 48–55.
  18. Grivas PD, Daignault S, Tagawa ST, et al. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014; 120(5): 692–701.
  19. Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol. 2020; 38(16): 1797–1806.
  20. Boyerinas B, Jochems C, Fantini M, et al. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015; 3(10): 1148–1157.
  21. Juliá EP, Amante A, Pampena MB, et al. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol. 2018; 9: 2140.
  22. Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018; 19(1): 51–64.
  23. Powles T, Park SeH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13): 1218–1230.
  24. Loriot Y, Powles T, Durán MC, et al. Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. J Clin Oncol. 2021; 39(6_suppl): 438–438.
  25. Hato S, Khong A, Vries Ide, et al. Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clin Cancer Res. 2014; 20(11): 2831–2837.
  26. Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016; 8(7): 821–837.
  27. Luo M, Fu L. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget. 2016; 7(20): 29794–29803.
  28. Song Z, Yu X, Zhang Y. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer. 2016; 99: 166–171.
  29. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008; 118(6): 1991–2001.
  30. Alva A, Csoszi T, Ozguroglu M, et al. Pembrolizumab combined with chemotherapy vs chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361. Pre- sented at the European Society for Medical Oncology (ESMO) Virtual Congress September 18–21, 2020.
  31. Galsky MD, Arija JÁ, Bamias A, et al. IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10236): 1547–1557.
  32. eUpdate – Bladder Cancer Treatment Recommendations Published: 16 July 2020. https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer.
  33. https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic.
  34. NCCN Bladder Cancer Guideliness – Version 3.2021. www.nccn.org.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl